(Reuters)—U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co. to treat adults with moderate to severe cases of plaque psoriasis.
The injectable drug known chemically as ixekizumab will be sold under the brand name Taltz, the U.S. Food and Drug Administration said.
Taltz works by blocking interleukein-17A, a protein that causes inflammation, which is believed to play a role in development of psoriasis.
In large, late-stage clinical trials, ixekizumab led to significant skin clearing compared with a placebo.
Pages: 1 | 2 | Single Page